Q4 FY2026 · ended Jun 30, 2026 · Revenue $31,050, +48.3% YoY · Filed Oct 13, 2026
Lunai Bioworks Inc. (LNAI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $31,050 and a net loss of $2.0 million. Free cash flow was -$1.8 million. As of Jun 30, 2026 it held $1.7 million in cash and investments and $350,035 in total debt.
Revenue
$31,050
+48.3% vs prior quarter
Net income
$-2.01M
+98.4% vs year-ago quarter
Operating cash flow
$-1.84M
-1.6% vs year-ago quarter
Free cash flow
$-1.84M
-79.3% vs prior quarter
EPS
$0.03
-98.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
5.03M
-97.8% vs year-ago quarter
Net cash
$1.36M
Q4 FY2026
Operating margin
-6888.6%
Q4 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LNAI (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Suite 906 Los Angeles, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1527728
- Former names
- RENOVARO INC. (until Aug 26, 2025); RENOVARO BIOSCIENCES INC. (until Feb 7, 2024); Enochian Biosciences Inc (until Aug 1, 2023); DanDrit Biotech USA, Inc. (until Feb 23, 2018); Putnam Hills Corp. (until Feb 11, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $31,050 | $20,942 | — | — | — |
| Operating income | -$2.1M | -$1.5M | -$1.8M | -$3.3M | -$126.9M |
| Net income | -$2.0M | -$2.6M | -$1.8M | $2.8M | -$126.7M |
| Diluted EPS | $0.03 | -$0.10 | -$0.08 | $0.13 | $3.16 |
| Operating cash flow | -$1.8M | -$1.0M | -$1.1M | -$1.3M | -$1.8M |
| Free cash flow | -$1.8M | -$1.0M | -$1.1M | — | — |
| Total assets | $9.9M | $9.9M | $6.7M | $7.0M | $8.2M |
| Total liabilities | $19.0M | $19.4M | $20.2M | $20.0M | $29.6M |
| Stockholders' equity | -$9.0M | -$9.6M | -$13.5M | -$13.0M | -$21.3M |
| Cash and investments | $1.7M | $3.2M | $491,645 | $624,808 | $92,700 |
| Total debt | $350,035 | $419,706 | $488,640 | $556,738 | $737,594 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice, Officer or director change, Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 16, 2026 |
| 10-K | Annual report | Oct 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Other events
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Other events
|
Jun 16, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Other events
|
May 20, 2026 | May 20, 2026 |
All 599 Lunai Bioworks Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.